S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:SGMT

Sagimet Biosciences (SGMT) Stock Price, News & Analysis

$5.42
-0.47 (-7.98%)
(As of 12/29/2023 ET)
Today's Range
$5.32
$6.00
50-Day Range
$2.23
$6.20
52-Week Range
$2.13
$18.33
Volume
153,445 shs
Average Volume
119,210 shs
Market Capitalization
$115.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.67

Sagimet Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
705.7% Upside
$43.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Sagimet Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,386 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($20.25) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

604th out of 950 stocks

Pharmaceutical Preparations Industry

293rd out of 442 stocks


SGMT stock logo

About Sagimet Biosciences Stock (NASDAQ:SGMT)

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SGMT Stock Price History

SGMT Stock News Headlines

Sagimet Biosciences (NASDAQ:SGMT) Trading Up 6.5%
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
Sagimet Biosciences Announces Leadership Changes
See More Headlines
Receive SGMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SGMT
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.67
High Stock Price Target
$67.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+705.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$115.88 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. George W. Kemble Ph.D. (Age 62)
    Executive Chairman of the Board
    Comp: $444.86k
  • Mr. David A. Happel (Age 61)
    CEO, President & Director
    Comp: $309.42k
  • Dr. Eduardo Bruno Martins DPhil (Age 60)
    M.D., Ph.D., Chief Medical Officer
    Comp: $536.83k
  • Mr. Urs Greber Ph.D.
    Co-Founder
  • Dr. Lucas Pelkmans Ph.D.
    Co-Founder
  • Mr. Anthony M. Rimac CPA (Age 59)
    CPA, CFO & Principal Accounting Officer
  • Ms. Elizabeth Rozek J.D. (Age 52)
    General Counsel & Chief Compliance Officer
  • Dr. Marie O'Farrell Ph.D.
    Senior Vice President of Research & Development














SGMT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sagimet Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sagimet Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMT shares.
View SGMT analyst ratings
or view top-rated stocks.

What is Sagimet Biosciences' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price objectives for Sagimet Biosciences' shares. Their SGMT share price targets range from $31.00 to $67.00. On average, they anticipate the company's stock price to reach $43.67 in the next year. This suggests a possible upside of 705.7% from the stock's current price.
View analysts price targets for SGMT
or view top-rated stocks among Wall Street analysts.

How have SGMT shares performed in 2023?

Sagimet Biosciences' stock was trading at $15.95 on January 1st, 2023. Since then, SGMT shares have decreased by 66.0% and is now trading at $5.42.
View the best growth stocks for 2023 here
.

When is Sagimet Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our SGMT earnings forecast
.

How were Sagimet Biosciences' earnings last quarter?

Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its earnings results on Monday, November, 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.67. The company earned $2 million during the quarter.

When did Sagimet Biosciences IPO?

(SGMT) raised $85 million in an initial public offering (IPO) on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $16.00 per share.

When does Sagimet Biosciences' lock-up period expire?

Sagimet Biosciences' lock-up period expires on Wednesday, January 10th. Sagimet Biosciences had issued 5,312,500 shares in its IPO on July 14th. The total size of the offering was $85,000,000 based on an initial share price of $16.00. After the expiration of Sagimet Biosciences' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

How do I buy shares of Sagimet Biosciences?

Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGMT) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -